Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. with Recent Stock Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through multiple stock purchases made on April 16 and 17, 2025.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., have reported changes in their beneficial ownership of Zymeworks Inc. common stock.
• On April 16, 2025, Qualified Fund purchased 69,339 shares at a weighted average price of $11.1637, with prices ranging from $10.9823 to $11.2339.
• On April 17, 2025, Qualified Fund purchased 51,344 shares at a weighted average price of $11.5197, with prices ranging from $11.5125 to $11.5214.
• Following these transactions, Qualified Fund holds 16,712,184 shares of Zymeworks Inc. common stock.
• EcoR1 Capital, as the investment advisor to the Funds, may be deemed to indirectly beneficially own these shares, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
• The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a major shareholder is increasing their position, suggesting confidence. However, it's a routine filing and doesn't contain groundbreaking news.

Positives

• EcoR1 Capital's increased investment in Zymeworks could be interpreted as a sign of confidence in the company's future prospects.

Risks

• The document does not explicitly mention any risks.
• However, it is important to note that investment decisions should be based on a thorough understanding of the company and its industry.

Industry Context

This announcement reflects ongoing investment activity within the biotechnology sector, where firms like Zymeworks are attracting capital from specialized investment firms such as EcoR1 Capital.

Comparison to Industry Standards

• Comparing EcoR1's investment strategy to other biotech-focused funds like Orbimed or RA Capital Management, it's evident that targeted investments in companies with promising therapeutic platforms are common.
• Similar to investments made by these funds in companies like CRISPR Therapeutics or Beam Therapeutics, EcoR1's increased stake in Zymeworks suggests a belief in the company's technology and market potential.
• The size of the investment is within the typical range for such funds, but the specific impact will depend on Zymeworks' performance relative to its peers in the antibody therapeutics space, such as Regeneron or Genmab.

Stakeholder Impact

• The increased stake by EcoR1 Capital could positively influence shareholder confidence.
• Employees may view this as a positive sign of the company's stability and growth potential.

Key Dates

Keywords

Zymeworks, EcoR1 Capital, Stock Purchase, Beneficial Ownership, Oleg Nodelman, Investment, Shares